IP Library Granted Patent US 9,504,702
Granted Patent B2
US 9,504,702 · App. 13/814,083 · Granted Nov 29, 2016

Methods of inhibition of protein fucosylation in vivo using fucose analogs

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,504,702
App. No.
13/814,083
Granted
Nov 29, 2016
Kind
B2
Abstract

The invention provides methods and compositions for the inhibition of fucosylation of proteins, including antibodies, in vivo by administration of a fucose analog.

Claims (13)

1. A method for the treatment of cancer in a human in need thereof, comprising administering orally to the human a therapeutically effective amount of a fucose analog, or a composition thereof,

wherein the cancer is a solid tumor having protein fucosylation; and

wherein each fucose analog has formulae (V) or (VI):

or a biologically acceptable salt or solvate thereof, wherein each fucose analog of formula (V) or (VI) can be the alpha or beta anomer or the corresponding aldose form;

wherein each of R 1 , R 3 , and R 4 is independently selected from the group consisting of —OH and —OC(O)C 1 -C 10 alkyl, R 2 is F, R 2a and R 3a are each H, and R 5 is —CH 3 .

2. The method of claim 1 wherein said fucose analog is 2-deoxy-2-fluoro-L-fucose.

3. The method of claim 1 wherein said fucose analog is 2-deoxy-2-fluoro-L-fucose peracetate.

4. The method of claim 1 further comprising administering a tumor-associated antigen or an antigenic fragment thereof as an immunogen.

5. The method of claim 1 further comprising administering a chemotherapeutic agent.

6. The method of claim 1 wherein the solid tumor is breast cancer.

7. The method of claim 1 wherein the solid tumor is lung cancer.

8. The method of claim 1 wherein the solid tumor is renal cell carcinoma.

9. The method of claim 1 wherein administration of the therapeutically effective amount is in the form of one or more dosage units.

Assignments (1)
CHANGE OF NAME Recorded Feb 18, 2021
From: SEATTLE GENETICS, INC.
To: SEAGEN INC.
Reel/Frame 055334/0754 →